Where Does the Industry Go from Here? Competitive Bidding Reform...

Published in Billing, Reimbursement, Audits and Compliance on February 11, 2019

WATERLOO, IA – Ok…The industry now has had time to digest the ESRD Final Rule and its impact. Where does the industry go from here?

The good news is that there is a two-year gap period before the next round of Bidding (until Dec. 31, 2020). This will allow providers time to work with their creditors and have a two-year period of relative stability.

 The bad news is there is a two-year gap period before the next round of bidding, which will delay any increase in rates that potentially could come from a new bidding process (that includes changes such as maximum bid, bid bonds, lead item bids, and others).

So, what do we do during this two-year period? We can’t get complacent – as stakeholders, we have to work at the federal level and at the state level. At the federal level we focus on legislation and regulatory action to address:

  • Non-Rural – Continue to advocate for higher reimbursement rates in areas deemed Non-Rural by CMS.
  • Competitive Bid – Prepare for CB Round 3. Provide input to CMS on proper product category definition, lead price analysis, capacity reforms, bona fide bidders, etc.
  • Budget Neutrality – Encourage legislation in 2019 for budget neutrality offset for oxygen.
  • CRT- Build on efforts in 2018 and gain momentum as we navigate through 2019.

At the state level, we need providers in coordination with state associations focused on the next two years.

  • Licensure – Level the playing field with out-of-state bidders and drop shipment of DME.
  • State Tax Exemption – While many states exempt state tax on DME, many do not, and some exempt only certain DME items.
  • State Medicaid / MCO Rates – Work with state legislators and DHHS on proper rates for DME.

We have a full plate of issues both at the federal and state levels. To accomplish our goals in 2019 and 2020 we are going to need strong state associations and provider involvement. Effective collaboration and joint efforts are vital. Now is not the time to rely on others to get it done; rather, use the available resources through our advocacy groups, and join with others to succeed for the future of the DMEPOS industry.

John E. Gallagher is vice president, Government Relations, VGM & Associates, Waterloo, Iowa.

View the original article here.


comments powered by Disqus

From Our Experts

CMS Audits Resume August 3, 2020 thumbnail CMS Audits Resume August 3, 2020 In this episode, we chat with Wayne van Halem and Kelly Grahovac of The van Halem Group about the CMS audits returning today, August 3, and what DMEPOS providers need to know. Member Q&A From The van Halem Group: New Order Requirement and Member Q&A From The van Halem Group: New Order Requirement and "Master List" I'm curious about this new order requirement. I see that Medicare updated the notice on 2/12/20, and I'm curious about the “Master List” of items that still needs a WOPD. I'm wondering if PAP equipment and supplies fall under the SWO or the WOPD. Can you help me understand? The Cost of Compliance – An Impassioned Plea to be Proactive thumbnail The Cost of Compliance – An Impassioned Plea to be Proactive Last year, The van Halem Group was engaged by several DME providers that were subject to a 6-year OIG lookback audit. Sadly, for companies that did not have a process in place for proactive chart audits, the 6-year look back resulted in a very expensive lesson. Lookback audits are here to stay, and it's never been more important for providers to have a comprehensive proactive compliance program, and this is one way that The van Halem Group can assist members. OIG to Review PMD Repairs and PAP Supplies thumbnail OIG to Review PMD Repairs and PAP Supplies The Office of Inspector General (OIG) has updated its work plan to include new reviews for PAP replacement supplies and power mobility device repairs. In a recent article from HME News, Medicare paid approximately $945.8 million for replacement supplies in 2017 and 2018, but OIG has previously found that most claims did not comply with Medicare requirements and that DME suppliers often did not have the documentation required to support the need for replacement supplies. Are Inhalation Drugs the Next OIG Six Year Lookback Audit? thumbnail Are Inhalation Drugs the Next OIG Six Year Lookback Audit? Since 2010, the CMS's Comprehensive Error Rate Testing (CERT) program has identified nebulizers and related drugs (i.e., inhalation drugs) among the top 20 supplies with the highest improper Medicare payments. Based on prior reviews, the Office of Inspector General (OIG) conducted a nationwide review to determine if the suppliers included in the review complied with Medicare requirements when billing for inhalation drugs. Ronda Says: Are You Ready for Oct. 21? Group II Support Surfaces Enter Prior Authorization Program for All States thumbnail Ronda Says: Are You Ready for Oct. 21? Group II Support Surfaces Enter Prior Authorization Program for All States CMS announced in Dec. 30, 2015 a finalized rule creating a program called Condition of Payment Prior Authorization Program for Certain DMEPOS items. The Value and Importance of Bid Calculators for Round 2021 Competitive Bidding thumbnail The Value and Importance of Bid Calculators for Round 2021 Competitive Bidding If someone would have told me a year ago that for the next round of Competitive Bidding (CB) a Durable Medical Equipment (DME) supplier could lose $100,000, $250,000, $500,000, or even $1,000,000 or more in revenue by bidding rates that were equal to the rates that are in place today, I would have said you were crazy. How Competitive Bidding Will Impact Reimbursement Rates for Non-Bid Areas thumbnail How Competitive Bidding Will Impact Reimbursement Rates for Non-Bid Areas So, you think that because you do not serve or operate within a competitive bid area (CBA), that Round 2021 of the Competitive Bidding (CB) program for DMEPOS products and services doesn't matter to you or doesn't impact you and your business? Think again!